In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)-Reference-Cited by-同舟云学术

In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)

Published:2016-05 Issue:5 Volume:60 Page:3163-3169
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

de Jonge Boudewijn L. M.¹,Karlowsky James A.²,Kazmierczak Krystyna M.²,Biedenbach Douglas J.²,Sahm Daniel F.²,Nichols Wright W.¹

Affiliation:

1. AstraZeneca Pharmaceuticals, Waltham, Massachusetts, USA

2. International Health Management Associates, Inc., Schaumburg, Illinois, USA

Abstract

ABSTRACT The activity of ceftazidime-avibactam was assessed against 961 isolates of meropenem-nonsusceptible Enterobacteriaceae . Most meropenem-nonsusceptible metallo-β-lactamase (MBL)-negative isolates (97.7%) were susceptible to ceftazidime-avibactam. Isolates that carried KPC or OXA-48-like β-lactamases, both alone and in combination with extended-spectrum β-lactamases (ESBLs) and/or AmpC β-lactamases, were 98.7% and 98.5% susceptible to ceftazidime-avibactam, respectively. Meropenem-nonsusceptible, carbapenemase-negative isolates demonstrated 94.7% susceptibility to ceftazidime-avibactam. Ceftazidime-avibactam activity was compromised only in isolates for which carbapenem resistance was mediated through metallo-β-lactamases.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.03042-15

Reference35 articles.

1. Grabe M Bjerklund-Johansen TE Botto H Çek M Naber KG Pickard RS Tenke P Wagenlehner F Wullt B. 2013. Guidelines on urological infections. European Association of Urology Arnhem the Netherlands. http://uroweb.org/wp-content/uploads/18_Urological-infections_LR.pdf.

2. Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections

3. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

4. Extended-Spectrum β-Lactamases: a Clinical Update

5. Carbapenemases: Partners in crime

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli;Antimicrobial Agents and Chemotherapy;2024-08-19

2. Efficacy of ceftazidime/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli;Acta Microbiologica et Immunologica Hungarica;2024-07-02

3. Combination Therapy for OXA-48 Carbapenemase-Producing Klebsiella Pneumoniae Bloodstream Infections in Premature Infant: A Case Report and Literature Review;Infection and Drug Resistance;2024-05

4. The Clinical Efficacy of Adding Ceftazidime/Avibactam to Standard Therapy in Treating Infections Caused by Carbapenem-Resistant Klebsiella pneumonia with blaOXA-48-like Genes;Antibiotics;2024-03-16

5. Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria;Antibiotics;2024-03-15